Complications of Cushing's syndrome: State of the art

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 7, 2016, Pages 611-629

  Pivonello, Rosario ^a   Isidori, Andrea M ^b   De Martino, Maria Cristina ^a   Newell Price, John ^c,d   Biller, Beverly M K ^e   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; COMPLICATION; CUSHING SYNDROME; HUMAN; IMMUNOPATHOLOGY; MENTAL DISEASE; METABOLIC SYNDROME X; MORTALITY; MUSCULOSKELETAL DISEASE; SEXUAL DYSFUNCTION;

CARDIOVASCULAR DISEASES; CUSHING SYNDROME; HUMANS; IMMUNE SYSTEM DISEASES; MENTAL DISORDERS; METABOLIC SYNDROME; MUSCULOSKELETAL DISEASES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 84970015485     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)00086-3     Document Type: Review

References (154)

1. Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A Cushing's syndrome. Endocrinol Metab Clin North Am 2008, 37:135-149. ix.
2. Newell-Price J, Bertagna X, Grossman AB, Nieman LK Cushing's syndrome. Lancet 2006, 367:1605-1617.
3. Steffensen C, Bak AM, Rubeck KZ, Jørgensen JO Epidemiology of Cushing's syndrome. Neuroendocrinology 2010, 92(suppl 1):1-5.
4. Pivonello R, De Leo M, Cozzolino A, Colao A The treatment of Cushing's disease. Endocr Rev 2015, 36:385-486.
5. Cushing H The basophil adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 1932, 50:137-195.
6. Feelders RA, Pulgar SJ, Kempel A, Pereira AM The burden of Cushing's disease: clinical and health-related quality of life aspects. Eur J Endocrinol 2012, 167:311-326.
7. Newell-Price J, Trainer P, Besser M, Grossman A The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998, 19:647-672.
8. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88:5593-5602.
9. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008, 93:1526-1540.
10. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008, 93:2454-2462.
11. Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015, 100:2807-2831. the Endocrine Society.
12. Crowley RK, Argese N, Tomlinson JW, Stewart PM Central hypoadrenalism. J Clin Endocrinol Metab 2014, 99:4027-4036.
13. Hochberg Z, Pacak K, Chrousos GP Endocrine withdrawal syndromes. Endocr Rev 2003, 24:523-538.
14. Grossman A, Johannsson G, Quinkler M, Zelissen P Therapy of endocrine disease: perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol 2013, 169:R165-R175.
15. Clayton RN Mortality in Cushing's disease. Neuroendocrinology 2010, 92(suppl 1):71-76.
16. Etxabe J, Vazquez JA Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994, 40:479-484.
17. Swearingen B, Biller BM, Barker FG, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 1999, 130:821-824.
18. Pikkarainen L, Sane T, Reunanen A The survival and well-being of patients treated for Cushing's syndrome. J Intern Med 1999, 245:463-468.
19. Lindholm J, Juul S, Jørgensen JO, et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001, 86:117-123.
20. Hammer GD, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 2004, 89:6348-6357.
21. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2007, 92:976-981.
22. Clayton RN, Raskauskiene D, Reulen RC, Jones PW Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 2011, 96:632-642.
23. Hassan-Smith ZK, Sherlock M, Reulen RC, et al. Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab 2012, 97:1194-1201.
24. Bolland MJ, Holdaway IM, Berkeley JE, et al. Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol (Oxf) 2011, 75:436-442.
25. Yaneva M, Kalinov K, Zacharieva S Mortality in Cushing's syndrome: data from 386 patients from a single tertiary referral center. Eur J Endocrinol 2013, 169:621-627.
26. Ntali G, Asimakopoulou A, Siamatras T, et al. Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 2013, 169:715-723.
27. Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients. J Clin Endocrinol Metab 2013, 98:1022-1030.
28. Dekkers OM, Horváth-Puhó E, Jørgensen JO, et al. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. J Clin Endocrinol Metab 2013, 98:2277-2284.
29. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen JO Mortality in Cushing's syndrome: a systematic review and meta-analysis. Eur J Intern Med 2012, 23:278-282.
30. Pivonello R, Faggiano A, Lombardi G, Colao A The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 2005, 34:327-339. viii.
31. Wang M The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr Metab (Lond) 2005, 2:3.
32. Pivonello R, De Leo M, Vitale P, et al. Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology 2010, 92(suppl 1):77-81.
33. Lee MJ, Pramyothin P, Karastergiou K, Fried SK Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim Biophys Acta 2014, 1842:473-481.
34. Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol 1996, 271:E317-E325.
35. Galton DJ, Wilson JP Lipogenesis in adipose tissue of patients with obesity and Cushing's disease. Clin Sci 1972, 43:17P.
36. Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003, 88:2527-2533.
37. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004, 61:768-777.
38. Giordano R, Picu A, Marinazzo E, et al. Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) 2011, 75:354-360.
39. Barahona MJ, Sucunza N, Resmini E, et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab 2009, 94:3365-3371.
40. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999, 84:2664-2672.
41. Geer EB, Shen W, Gallagher D, et al. MRI assessment of lean and adipose tissue distribution in female patients with Cushing's disease. Clin Endocrinol (Oxf) 2010, 73:469-475.
42. Albiger N, Testa RM, Almoto B, et al. Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res 2006, 38:405-410.
43. Geer EB, Shen W, Strohmayer E, Post KD, Freda PU Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab 2012, 97:1702-1711.
44. Giordano C, Guarnotta V, Pivonello R, et al. Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?. Eur J Endocrinol 2014, 170:311-319.
45. Pecori Giraldi F, Moro M, Cavagnini F Gender-related differences in the presentation and course of Cushing's disease. J Clin Endocrinol Metab 2003, 88:1554-1558. the Study Group on the Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of Endocrinology.
46. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009, 94:223-230.
47. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 2008, 158:91-99.
48. Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing's disease: is it worth a try?. J Clin Endocrinol Metab 2014, 99:1623-1630.
49. Moncet D, Morando DJ, Pitoia F, Katz SB, Rossi MA, Bruno OD Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing's syndrome. Medicina (B Aires) 2007, 67:26-31.
50. Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol 2012, 167:473-481.
51. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012, 97:2039-2049. the SEISMIC Study Investigators.
52. Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009, 160:1003-1010.
53. Katznelson L, Loriaux DL, Feldman D, Braunstein GD, Schteingart DE, Gross C Global clinical response in Cushing's syndrome patients treated with mifepristone. Clin Endocrinol (Oxf) 2014, 80:562-569.
54. Wallia A, Colleran K, Purnell JQ, Gross C, Molitch ME Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects. Diabetes Care 2013, 36:e147-e148.
55. Pivonello R, Petersenn S, Newell-Price J, et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a phase III study. Clin Endocrinol (Oxf) 2014, 81:408-417. the Pasireotide B2305 Study Group.
56. Valassi E, Santos A, Yaneva M, et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011, 165:383-392. the ERCUSYN Study Group.
57. Pivonello R, De Martino MC, De Leo M, et al. Cushing's syndrome: aftermath of the cure. Arq Bras Endocrinol Metabol 2007, 51:1381-1391.
58. Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards CR, Besser GM Metyrapone in long-term management of Cushing's disease. BMJ 1977, 2:215-217.
59. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012, 366:914-924. the Pasireotide B2305 Study Group.
60. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013, 98:3446-3453.
61. Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Pituitary 2014, 17:180-186.
62. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006, 91:3954-3961.
63. Munir A, Newell-Price J Management of diabetes mellitus in Cushing's syndrome. Neuroendocrinology 2010, 92(suppl 1):82-85.
64. Isidori AM, Graziadio C, Paragliola RM, et al. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens 2015, 33:44-60. the ABC Study Group.
65. Gómez RM, Albiger NM, Díaz AG, Moncet D, Pitoia FA, Bruno OD Effect of hypercortisolism control on high blood pressure in Cushing's syndrome. Medicina (B Aires) 2007, 67:439-444.
66. Isidori AM, Minnetti M, Sbardella E, Graziadio C, Grossman AB Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol 2015, 173:R101-R113.
67. Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. Eur J Endocrinol 2010, 162:331-340.
68. Jyotsna VP, Naseer A, Sreenivas V, Gupta N, Deepak KK Effect of Cushing's syndrome-endogenous hypercortisolemia on cardiovascular autonomic functions. Auton Neurosci 2011, 160:99-102.
69. Torpy DJ, Mullen N, Ilias I, Nieman LK Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 2002, 970:134-144.
70. Muiesan ML, Lupia M, Salvetti M, et al. Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol 2003, 41:2275-2279.
71. Pecori Giraldi F, Toja PM, De Martin M, et al. Circadian blood pressure profile in patients with active Cushing's disease and after long-term cure. Horm Metab Res 2007, 39:908-914.
72. Storr HL, Isidori AM, Monson JP, Besser GM, Grossman AB, Savage MO Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis. J Clin Endocrinol Metab 2004, 89:3818-3820.
73. Bertagna X, Pivonello R, Fleseriu M, et al. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 2014, 99:1375-1383.
74. Castinetti F, Brue T, Conte-Devolx B The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes 2012, 19:295-299.
75. Kamenický P, Redheuil A, Roux C, et al. Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab 2014, 99:E2144-E2153.
76. Ainscough JF, Drinkhill MJ, Sedo A, et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 2009, 81:592-600.
77. Brilla CG, Weber KT Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893-901.
78. Pecori Giraldi F, Toja PM, Michailidis G, et al. High prevalence of prolonged QT interval duration in male patients with Cushing's disease. Exp Clin Endocrinol Diabetes 2011, 119:221-224.
79. Faggiano A, Melis D, Alfieri R, et al. Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease. J Clin Endocrinol Metab 2005, 90:6616-6622.
80. Yiu KH, Marsan NA, Delgado V, et al. Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. Eur J Endocrinol 2012, 166:27-34.
81. van der Pas R, Leebeek FW, Hofland LJ, de Herder WW, Feelders RA Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 2013, 78:481-488.
82. van der Pas R, de Bruin C, Leebeek FW, et al. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab 2012, 97:1303-1310.
83. Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002, 87:3662-3666.
84. Levis JT ECG diagnosis: hypokalemia. Perm J 2012, 16:57.
85. Arteaga E, Fardella C, Campusano C, Cárdenas I, Martinez P Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition. J Endocrinol Invest 1999, 22:857-859.
86. Fareau GG, Vassilopoulou-Sellin R Hypercortisolemia and infection. Infect Dis Clin North Am 2007, 21:639-657. viii.
87. Kovalovsky D, Refojo D, Holsboer F, Arzt E Molecular mechanisms and Th1/Th2 pathways in corticosteroid regulation of cytokine production. J Neuroimmunol 2000, 109:23-29.
88. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005, 90:4955-4962.
89. Sarlis NJ, Chanock SJ, Nieman LK Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab 2000, 85:42-47.
90. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, et al. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer 2011, 117:4381-4389.
91. Broder MS, Neary MP, Chang E, Ludlam WH Incremental healthcare resource utilization and costs in US patients with Cushing's disease compared with diabetes mellitus and population controls. Pituitary 2015, 18:796-802.
92. Bakker RC, Gallas PR, Romijn JA, Wiersinga WM Cushing's syndrome complicated by multiple opportunistic infections. J Endocrinol Invest 1998, 21:329-333.
93. Lionakis MS, Kontoyiannis DP Glucocorticoids and invasive fungal infections. Lancet 2003, 362:1828-1838.
94. Rizwan A, Sarfaraz A, Jabbar A, Akhter J, Islam N Case report: nocardia infection associated with ectopic cushings. BMC Endocr Disord 2014, 14:51.
95. Graham BS, Tucker WS Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med 1984, 101:334-338.
96. Razavi B, O'Toole J, Schilling M, Razavi M Cryptococcal meningitis, an endocrine emergency?. Lancet 2000, 355:1426.
97. Oosterhuis JK, van den Berg G, Monteban-Kooistra WE, et al. Life-threatening Pneumocystis jiroveci pneumonia following treatment of severe Cushing's syndrome. Neth J Med 2007, 65:215-217.
98. Takasu N, Komiya I, Nagasawa Y, Asawa T, Yamada T Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing's syndrome due to an adrenocortical adenoma. N Engl J Med 1990, 322:1708-1712.
99. Takasu N, Ohara N, Yamada T, Komiya I Development of autoimmune thyroid dysfunction after bilateral adrenalectomy in a patient with Carney's complex and after removal of ACTH-producing pituitary adenoma in a patient with Cushing's disease. J Endocrinol Invest 1993, 16:697-702.
100. Colao A, Pivonello R, Faggiano A, et al. Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf) 2000, 53:13-19.
101. da Mota F, Murray C, Ezzat S Overt immune dysfunction after Cushing's syndrome remission: a consecutive case series and review of the literature. J Clin Endocrinol Metab 2011, 96:E1670-E1674.
102. Neto MB, Machado MC, Mesquita F, et al. Thymus hyperplasia after resolution of hypercortisolism in ACTH-dependent Cushing's syndrome: the importance of thymic vein catheterization. Eur J Endocrinol 2006, 154:807-811.
103. Di Somma C, Pivonello R, Loche S, et al. Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. Clin Endocrinol (Oxf) 2002, 56:153-158.
104. Di Somma C, Pivonello R, Loche S, et al. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf) 2003, 58:302-308.
105. Kawamata A, Iihara M, Okamoto T, Obara T Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study. World J Surg 2008, 32:890-896.
106. Minetto M, Reimondo G, Osella G, Ventura M, Angeli A, Terzolo M Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporos Int 2004, 15:855-861.
107. Ohmori N, Nomura K, Ohmori K, Kato Y, Itoh T, Takano K Osteoporosis is more prevalent in adrenal than in pituitary Cushing's syndrome. Endocr J 2003, 50:1-7.
108. Tauchmanovà L, Pivonello R, De Martino MC, et al. Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. Eur J Endocrinol 2007, 157:359-366.
109. van der Eerden AW, den Heijer M, Oyen WJ, Hermus AR Cushing's syndrome and bone mineral density: lowest Z scores in young patients. Neth J Med 2007, 65:137-141.
110. dos Santos CV, Vieira Neto L, Madeira M, et al. Bone density and microarchitecture in endogenous hypercortisolism. Clin Endocrinol (Oxf) 2015, 83:468-474.
111. Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995, 80:2859-2865.
112. Randazzo ME, Grossrubatscher E, Dalino Ciaramella P, Vanzulli A, Loli P Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary 2012, 15:193-201.
113. Tauchmanovà L, Pivonello R, Di Somma C, et al. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 2006, 91:1779-1784.
114. Trementino L, Appolloni G, Ceccoli L, et al. Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporos Int 2014, 25:913-921.
115. Barahona MJ, Sucunza N, Resmini E, et al. Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome. J Bone Miner Res 2009, 24:1841-1846.
116. Di Somma C, Colao A, Pivonello R, et al. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol (Oxf) 1998, 48:655-662.
117. Chiodini I, Carnevale V, Torlontano M, et al. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. J Clin Endocrinol Metab 1998, 83:1863-1867.
118. Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol 2006, 154:109-118.
119. Vestergaard P, Lindholm J, Jørgensen JO, et al. Increased risk of osteoporotic fractures in patients with Cushing's syndrome. Eur J Endocrinol 2002, 146:51-56.
120. Füto L, Toke J, Patócs A, et al. Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing's syndrome. Osteoporos Int 2008, 19:941-949.
121. Canalis E, Mazziotti G, Giustina A, Bilezikian JP Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18:1319-1328.
122. Weinstein RS Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011, 365:62-70.
123. Seibel MJ, Cooper MS, Zhou H Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 2013, 1:59-70.
124. Luisetto G, Zangari M, Camozzi V, Boscaro M, Sonino N, Fallo F Recovery of bone mineral density after surgical cure, but not by ketoconazole treatment, in Cushing's syndrome. Osteoporos Int 2001, 12:956-960.
125. Scillitani A, Mazziotti G, Di Somma C, et al. Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. Osteoporos Int 2014, 25:441-446. the ABC Group.
126. Minetto MA, Lanfranco F, Motta G, Allasia S, Arvat E, D'Antona G Steroid myopathy: some unresolved issues. J Endocrinol Invest 2011, 34:370-375.
127. Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013, 45:2163-2172.
128. Aulinas A, Colom C, Ybarra J, et al. Immediate and delayed postoperative morbidity in functional and non-functioning pituitary adenomas. Pituitary 2012, 15:380-385.
129. Pivonello R, Simeoli C, De Martino MC, et al. Neuropsychiatric disorders in Cushing's syndrome. Front Neurosci 2015, 9:129.
130. Sonino N, Fava GA Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 2001, 15:361-373.
131. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998, 19:269-301.
132. Jacobs BL, van Praag H, Gage FH Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 2000, 5:262-269.
133. Patil CG, Lad SP, Katznelson L, Laws ER Brain atrophy and cognitive deficits in Cushing's disease. Neurosurg Focus 2007, 23:E11.
134. Bleicken B, Hahner S, Loeffler M, et al. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2010, 72:297-304.
135. Kaltsas GA, Korbonits M, Isidori AM, et al. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?. Clin Endocrinol (Oxf) 2000, 53:493-500.
136. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 1998, 83:3083-3088.
137. Gabrilove JL, Nicolis GL, Sohval AR The testis in Cushing's syndrome. J Urol 1974, 112:95-99.
138. McKenna TJ, Lorber D, Lacroix A, Rabin D Testicular activity in Cushing's disease. Acta Endocrinol (Copenh) 1979, 91:501-510.
139. Pivonello R, De Martino MC, Auriemma RS, et al. Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. J Endocrinol Invest 2014, 37:99-112.
140. Whirledge S, Cidlowski JA Glucocorticoids, stress, and fertility. Minerva Endocrinol 2010, 35:109-125.
141. Unuane D, Tournaye H, Velkeniers B, Poppe K Endocrine disorders & female infertility. Best Pract Res Clin Endocrinol Metab 2011, 25:861-873.
142. Brzana J, Yedinak CG, Hameed N, Plesiu A, McCartney S, Fleseriu M Polycystic ovarian syndrome and Cushing's syndrome: a persistent diagnostic quandary. Eur J Obstet Gynecol Reprod Biol 2014, 175:145-148.
143. Putignano P, Bertolini M, Losa M, Cavagnini F Screening for Cushing's syndrome in obese women with and without polycystic ovary syndrome. J Endocrinol Invest 2003, 26:539-544.
144. Pall ME, Lao MC, Patel SS, et al. Testosterone and bioavailable testosterone help to distinguish between mild Cushing's syndrome and polycystic ovarian syndrome. Horm Metab Res 2008, 40:813-818.
145. Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006, 91:2-6.
146. Iannaccone A, Gabrilove JL, Sohval AR, Soffer LJ The ovaries in Cushing's syndrome. N Engl J Med 1959, 261:775-780.
147. Kaltsas GA, Isidori AM, Kola BP, et al. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab 2003, 88:2634-2643.
148. Ferraù F, Losa M, Cotta OR, et al. Course of pregnancies in women with Cushing's disease treated by gamma-knife. Gynecol Endocrinol 2012, 28:827-829.
149. Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 2005, 90:3077-3083.
150. Bronstein MD, Machado MC, Fragoso MC Management of endocrine disease: management of pregnant patients with Cushing's syndrome. Eur J Endocrinol 2015, 173:R85-R91.
151. Luton JP, Thieblot P, Valcke JC, Mahoudeau JA, Bricaire H Reversible gonadotropin deficiency in male Cushing's disease. J Clin Endocrinol Metab 1977, 45:488-495.
152. Pozza C, Graziadio C, Giannetta E, Lenzi A, Isidori AM Management strategies for aggressive Cushing's syndrome: from macroadenomas to ectopics. J Oncol 2012, 2012:685213.
153. Davidovici BB, Orion E, Wolf R Cutaneous manifestations of pituitary gland diseases. Clin Dermatol 2008, 26:288-295.
154. Stratakis CA, Mastorakos G, Mitsiades NS, Mitsiades CS, Chrousos GP Skin manifestations of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia. Pediatr Dermatol 1998, 15:253-258.